Ruboxistaurin Eli Lilly

IDrugs

Volumn 6, Issue 2, 2003, Pages 159-163

  Wheeler, Glen D ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [4 (4,4' DIFLUOROBENZHYDRYLIDENE)PIPERIDINO]ETHYL] 2,3 DIHYDRO 2 THIOXO 4(1H) QUINAZOLINONE; DIACYLGLYCEROL KINASE INHIBITOR; DRUG METABOLITE; LY 338522; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE MODEL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; ENZYME INHIBITORS; HUMANS; PROTEIN KINASE C; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 0037293351     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. 204195 Macrocycle (bis)indolylmaleimides: Isozyme selective inhibitors of protein kinase C (PKC). Jirousek MR, Gillig JR, Heath WF, Johnston CM, McDonald JH III, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Beavsky M et al. ACS 211th Annual Meeting New Orleans, LA, USA (1996)
2. 215881 (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H -dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase Cβ. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M et al J Med Chem 1996 39 14 2664-2671 A novel series of 14-membered macrocycles containing a N-N′-bridged bisinodlylmaleimide moiety was described. The cellular activity of the series was assessed using bovine retinal capillary endothelial cells.
3. 217601 Trials underway. Clin Trials Monitor 1996 5 8 6-14
4. 279021 Specific retinal diacylglycerol and protein kinase C β isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Bursell SE, Takagi C, Clermont AC, Takagi H, Mori F, Ishii H, King GL Invest Opthalmol Vis Sci 1997 38 13 2711-2720 DAG elevation and subsequent PKC-β isoform activation are the primary biochemical sequelae responsible for the development of the abnormal retinal hemodynamics observed in diabetic rats.
5. 279025 Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL Science 1996 272 5262 728-731 Ruboxistaurin normalized diabetes-induced elevations of PKC-β activity in diabetic rats.
6. 2+-ATPase in the retina are mediated in large part by PKC-β.
7. 316821 US Equity Research: Eli Lilly. Deutsche Banc Alex Brown 1999 February 01
8. 326984 Lilly announces Evista is granted priority review status for osteoporosis treatment submission. Eli Lilly & Co Press Release 1999 June 04
9. 329671 American Diabetes Association - 59th Annual Meeting, San Diego, CA, USA. Hopfner R IDDB Meeting Report 1999 June 19-22 Ruboxistaurin caused widespread vascular barrier dysfunction in control rats and in the brain and heart of diabetic rats, and failed to prevent impaired vascular barrier function induced by diabetes.
10. 332760 Treatment with the protein kinase C β inhibitor, LY333531, attenuates the development of impaired endothelium-dependent vasodilatation in the mesenteric vasculature of diabetic rats. Jack A, Cameron NE, Cotter MA 59th Ann Meet Am Diabetes Assoc Abs 0558 1999
11. 373270 Salt form selection and characterization of LY333531 mesylate monohydrate. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL Int J Pharm 2000; 198 2 239-247
12. 427113 Healthcare: Pharmaceuticals: Pharmaceutical industry review. Rubin J, Yu N, Sone T Morgan Stanley Dean Witter 2001 September 27
13. 429318 Protein Kinases in Drug Discovery & Development, Newark, NJ, USA. Hadari Y IDDB Meeting Report 2001 October 15-16
14. 430576 Eli Lilly - R&D meeting highlights broad, impressive pipeline attributes. Kulju K, Whysall C, Beall MA Credit Suisse Fist Boston Corporation 2001 October 24
15. 454538 LY333531 treatment improves diabetic peripheral neuropathy (DPN) with symptoms, The Mbbq Study Group. Vinik A, Tesfaye S, Zhang D, Bastyr E Diabetes 2002 51 2 A321-OR
16. 454973 Data presented at ADA reveal Lilly's PKC β inhibitor improved symptomatic diabetic peripheral neuropathy Lilly plans US regulatory submission in 2004 six phase III diabetic microvascular complication trials underway in 2002. Eli Lilly & Co Press Release 2002 June 17
17. 455001 American Diabetes Association - 62nd Scientific Sessions (Part IV) - Overnight Report, San Francisco, CA, USA. Mackay J IDDB Meeting Report 2002 June 14-18
18. 456670 Potential new medical therapies for diabetic retinopathy: Protein kinase C inhibitors. Frank RN Am J Ophthalmol 2002 133 5 693-698
19. 456671 Protein kinase C and the development of diabetic vascular complications. Way KJ, Katai N, King GL Diabetic Med 2001 18 12 945-959
20. 456676 PKC-β inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Miyamoto K, Nishiwaki H, Honda Y, Ogura Y Invest Opthalmol Vis Sci 2000 41 9 2702-2706 Ruboxistaurin might prevent microcirculatory flow disturbances caused by trapped leukocytes in the early diabetic retina.
21. 463070 Lilly's PKC β inhibitor improves symptoms associated with diabetic peripheral neuropathy in phase II trials. Eli Lilly & Co Press Release 2002 September 02
22. 474244 Clinical trials of PKCβ inhibitor completed for the treatment of diabetic retinopathy and diabetic macular edema. Eli Lilly & Co Press Release 2002 December 16
23. 475367 Effects of the protein kinase Cβ inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Cotter MA, Jack AM, Cameron NE Clin Sci (Lond) 2002 103 3 311-321
24. 475372 The interactions of a selective protein kinase C β inhibitor with the human cytochromes P450. Ring BJ, Gillespie JS, Binkley SN, Campanale KM, Wrighton SA Drug Metab Dispos 2002 30 9 957-961
25. 475677 Eli Lilly & Co - Presentation to the JP Morgan H&Q 21st Annual Healthcare Conference. Eli Lilly & Co Company Presentation 2003 January 06
26. 475773 Look into my eyes - PKC delayed in EU. Lehman Brothers Inc 2002 December 17